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likely via MASP-1/2 – heparin interaction.
Conclusions: Our data identiﬁes small heparin-derived oligosac-
charide inhibitors speciﬁc for the LP. We show that the LP
inhibitory effect of GAGs is via blocking the enzymatic activity of
the MASP enzymes. Binding of the MBL-MASP complex to
immobilized heparin indicates that heparan sulfate/heparin struc-
tures on cells and in extracellular matrix in vivo might act as
docking platforms for the MBL-MASP complex. These results
might be important for renal diseases with LP involvement.
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Introduction: B cell depletion, most commonly with rituximab
(RTX), has emerged as a potential therapeutic strategy in SLE,
particularly in patients who are unresponsive to, or intolerant of,
standard therapy. Ofatumumab is a fully humanised anti-CD20
monoclonal antibody directed against distinct extra-cellular epitope
on CD20, which has shown efﬁcacy in the treatment of haemato-
logical malignancy. Since 2012, we have been using ofatumumab on
compassionate grounds in patients with SLE for whom B cell
depletion is deemed a desirable therapeutic approach, but who are
allergic to RTX.
Methods: This is a retrospective report of SLE cases treated with
ofatumumab at our centre between 2012-2015. Data are reported as
medians +/- IQR, and comparisons are by non-parametric testing,
unless otherwise stated.
Results: In total, 15 patients received ofatumumab: all female, mean
age 33 years, median duration of SLE 7.5 years (range 1-18). 46%
had previously been treated with cyclophosphamide and all had
previously received RTX (median time since last treatment 4.5
months). All had severe infusion reactions to RTX previously. Two
patients demonstrated infusions reactions to ofatumumab, such that
they did not receive full dosing and have therefore been excluded
from subsequent analysis.
Of the remaining 13 cases, ten were treated for disease ﬂares
complicated by lupus nephritis (LN); three patients were treated for
extra-renal disease. Our standard treatment protocol is ofatumumab
2x700mg iv doses, with MMF maintenance and minimal steroids.
Following treatment, two patients did not achieve B cell depletion
(BCC<20). In those who did deplete, the median time to depletion
was 16 days, and to subsequent reconstitution (BCC>20) 4.8
months (see Figure). Treatment was associated with signiﬁcant
improvements in serological markers of disease activity at 6 months
(see Figure & Table).Kidney International Reports (2016) 1, S1–S22At 0 months At 6 months p valueANA, titre (median+/-IQR) 2560 (240-2560) 320 (200-2080) 0.012dsDNA, iu (median+/-IQR) 331 (234-717) 132 (73-429) 0.001C3, g/L (median+/-IQR) 0.69 (0.52-0.99) 0.83 (0.65-1.10) 0.022C4, g/L (median+/-IQR) 0.12 (0.08-0.18) 0.14 (0.07-0.25) nsThree patients with LN did not respond to treatment (>1.5x
rise in serum creatinine at 6 months). The remaining patients
had stable renal function (<10% increase or improved serum
creatinine) with improved proteinuria (median uPCR 424 to
99 mg/mmol) at 6 months. At last followup (median duration
32months), no opportunistic infections, malignancies, new episodes
of hypogammaglobulinaemia, or deaths have been observed. Three
patients had further severe disease ﬂares requiring hospitalisation
and escalation of treatment.
Conclusions: In this heavily pre-treated cohort, with longstanding
SLE refractory to conventional treatment, ofatumumab was effec-
tive for B cell depletion in patients who were intolerant of ritux-
imab. Treatment was associated with serological and clinical
response, although a proportion of patients had progressive disease.
No unexpected safety signals were seen. Larger controlled studies
are desirable to further deﬁne the role of ofatumumab in the
treatment of SLE. Pending these studies, ofatumumab may be
considered for patients who are intolerant of RTX, and for whom B
cell depletion is still a desirable treatment strategy.
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Introduction: Cytomegalovirus (CMV) is a frequently encountered
opportunistic pathogen in renal transplant recipients (RTR). Spec-
trum of CMV infection ranges from latent infection to life-threat-
ening multisystem disease. Current KDIGO guidelines recommend
RTR to receive a biologic induction agent and all RTR (except in D-/
R- CMV serology) to receive chemoprophylaxis for CMV infection
with oral ganciclovir or valganciclovir for at least 3 months post
transplantation. Currently no guidelines exist for use of CMV
prophylaxis in patients transplanted without a biologic induction.S3
